

AD \_\_\_\_\_

Award Number DAMD17-97-1-7048

TITLE: Characterization of BRCA2 Transcriptional Regulation

PRINCIPAL INVESTIGATOR: Fergus Couch, Ph.D.

CONTRACTING ORGANIZATION: Mayo Foundation  
Rochester, Minnesota 55905

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> August 1999	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Aug 98 - 31 Jul 99)	
<b>4. TITLE AND SUBTITLE</b> Characterization of BRCA2 Transcriptional Regulation			<b>5. FUNDING NUMBERS</b> DAMD17-97-1-7048	
<b>6. AUTHOR(S)</b> Fergus Couch, Ph.D.				
Mayo Foundation Rochester, Minnesota 55905			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b>				
<b>14. SUBJECT TERMS</b> Breast Cancer			<b>15. NUMBER OF PAGES</b> 9	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

       Where copyrighted material is quoted, permission has been obtained to use such material.

       Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

       Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

F. Couch  
PI - Signature

Date

## Table of Contents

Cover	1
SF 298	2
Foreword	3
Table of Contents	4
Overview	5

## **1999 Annual Report DAMD17-97-1-7048**

### **Overview**

The purpose of this award is to study the transcriptional regulation of the BRCA2 breast cancer predisposition gene with the goal of identifying agents capable of modulating BRCA2 expression. The most recent report for this grant was submitted on February 9<sup>th</sup>, 1999. The delay in submission resulted from the renegotiation and transfer of the grant to the Mayo Clinic and Foundation. Therefore, this report will describe the work that has been completed since February.

### **Experimental Results**

#### **Identification of the basic transcription regulatory region of BRCA2 promoter.**

In the previous report the delineation of an approximately 900bp region of the BRCA2 promoter that is responsible for basal transcriptional regulation of BRCA2 in MCF7 and 293T cells was described. Further characterization of this region has been undertaken by testing transcription from deletion mutants of the promoter in a luciferase reported assay. Briefly, each BRCA2 experimental reporter construct was transfected into MCF-7 breast epithelial cell line with a construct of renilla luciferase (HSV-TK) gene, which was used as an internal control for normalizing the activity of the experimental reporter. The firefly and renilla luciferase activities were detected in the cell lysates after 48 hours post-transfection. Relative firefly luciferase activity was measured as the ratio of the activity of firefly luciferase to renilla luciferase. The transcription activity of different mutants of the 8 kb region are shown in Figure 1. The results of transfection of the mutants indicated that the BRCA2 promoter is regulated in a complex fashion. Several regions appear to contribute 2 to 3 fold activation or repression. Mild 3 fold repression is observed between -582 and -515. Activation (2 fold) is observed between +110 and +181, while a 3 fold effect is present upon deletion of the region between +110 and 0 (transcription start site), and between -58 and -144. While these changes are statistically significant and suggest the presence of activation and repression elements, it is also possible that alterations in the size of the promoter region in the luciferase construct may artifactually induce these effects. However, a 20 fold loss of luciferase activity was observed following deletion of a 40 bp region (-58 to -18), suggesting that this region contains cis-elements that are critical for regulation of basal transcriptional activity of the BRCA2 promoter. This work represents an extension of the research proposed in Tasks 1, 4, 5, and 6.

#### **Further Characterization of the 44 base pair nucleotides.**

The 40bp region will include any elements that overlap this region. Therefore, we extended the region to 44bp to include a number of overlapping sites including USF, c-myc, and CDE. The 44bp interval was predicted to contain binding sites for several transcription factors, such as c-myc, activating transcription factor (ATF), and upstream stimulatory factor (USF), and aryl hydrocarbon receptor which binds the xenobiotic-responsive element (XRE). A further series of deletions were constructed to more accurately map the actual controlling element. Deletion of 10 bp from -58 to -50 did not

affect activity. Deletion of 16 more nucleotides (from -49 to -35, including two XRE motifs) resulted in 2-fold loss of luciferase activity. Similar results were obtained by point mutation of XRE sites, indicating that XRE may be involved in BRCA2 transcription up-regulation. The sequence from -34 to -14 contained two repeating sequences (GCGTCACG) and overlapping consensus binding sites for ATF, c-myc, USF, and CDE (centromere DNA element). Substitution of the GCGTCACG nucleotides (from -33 to -26) and / or the CGTCACGTG nucleotides from -24 to -16 by TAACTATT resulted in 10 to 100 fold loss of luciferase activity (Figure 2). This suggests that an element within the -33 to -26 sequence is required for transcription of the BRCA2 promoter, while an element located between -24 to -16 is an important contributor to promoter function. Given the repetitive nature of this region it is likely that homo or heterodimerization of transcription factors binding to these repeats controls BRCA2 transcription. This work in part addresses the research proposed in Tasks 6 and 7 of the SOW.

**USF may be an important factor in the BRCA2 transcription regulation.** In order to identify the specific cis-acting elements from the -33 to -14 region, and the specific transcription factors that bound to these elements we performed protein-DNA binding assays. Electrophoretic mobility shift assays were performed using oligonucleotide probes containing either wildtype sequence for the repeat region (-34 to -14) or mutations of either and both of the repeat sequences. Gel shift and competition assays of MCF7 lysates with these oligonucleotides detected two specific protein-DNA complexes. The larger complex was ablated when the first repeat sequence from -33 to -26 was substituted with TAACTATT (probe: M-1). The smaller complex was not detected when the wild type sequence (-24- to -14) was replaced by TAACTATT (probe: M-2). Furthermore, the smaller complex was super shifted by antibody against USF (kindly provided by Michele Sawadogo) but was not affected by antibodies against c-myc (Santa Cruz Biotechnology) or ATF2 (Santa Cruz Biotechnology). The protein-DNA binding experiments suggest that USF can specifically interact with its DNA binding motif in BRCA2 promoter in the -24 to -14 region. Thus, USF may be an important regulator of BRCA2 expression. However, the protein component of the larger complex which is necessary for BRCA2 transcription has not yet been identified. This work in part addresses the aims of Tasks 7 and 9 of the SOW.

#### Future Experiments

- 1) To identify the transcription factor that binds to the -34 to -26 element.
- 2) To reconstitute activation of the BRCA2 promoter by expression of USF and the unknown binding promoter
- 3) To assess the role of homo or heterodimerization of these proteins in activation of the BRCA2 promoter.
- 4) To identify regulatory elements in the other activating and repressing domains of the promoter.
- 5) To identify modulating agents that contribute to regulation of the promoter. While this work was proposed for months 2-14 (Tasks 2 and 3), it has been delayed while

we have concentrated on the experiments described above. This work will now be undertaken in conjunction with Task 8.

Figure 1: Identification of the basic transcription regulatory region of BRCA2 promoter





